Prof. Paul Parren Gyes BV, The Netherlands

Prof. dr. Paul W.H.I. Parren is a pioneer in translating antibody knowledge into innovative biologic drugs for treating human diseases. He holds a PhD in molecular immunology from the University of Amsterdam (1992). Prof. Parren was an Associate Professor at The Scripps Research Institute in La Jolla, California. From 2002-2017,... read morehe led research and preclinical development at Genmab, and from 2018-2023, he headed R&D at LAVA Therapeutics NV, bringing it to a clinical-stage, NASDAQ-listed, biotechnology company. His work contributed to nine FDA and EMA-approved therapeutic antibodies (incorporated in eleven antibody products), including four therapeutics from the DuoBody bispecific antibody platform. He is a tenured Professor of Molecular Immunology at the LUMC in Leiden, chairs the Board of Directors of the non-profit trade organization The Antibody Society, and provides independent drug development advice through Sparring Bioconsult BV. He cofounded Gyes BV (2022), Moirea BV and Olethros BV (2024), an ecosystem of start-up companies exploring the development of highly selective multifunctional antibody therapeutics.